- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | TScan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Mo | TScan Therapeutics, Inc.: TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation | 253 | GlobeNewswire (Europe) | 11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism following TSC-101 TSC-101 continues to be... ► Artikel lesen | |
| 04.06. | Cellares and TScan to assess automated manufacturing of TSC-101 therapy | 1 | Pharmaceutical Technology | ||
| 03.06. | Cellares, TScan Partner to Automate Manufacture of TCR-T Candidate | 1 | Contract Pharma | ||
| 22.05. | TScan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| TSCAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.05. | TScan Therapeutics GAAP EPS of -$0.22 misses by $0.01, revenue of $1M misses by $1.5M | 1 | Seeking Alpha | ||
| 06.05. | TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates | 1 | Zacks | ||
| 06.05. | TScan Therapeutics, Inc.: TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | 278 | GlobeNewswire (Europe) | Early data on patients treated in Cohort C of the ALLOHA Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2) planned for the second quarter... ► Artikel lesen | |
| 06.05. | TScan Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.05. | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.04. | TScan Therapeutics, Inc.: TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting | 4 | GlobeNewswire (USA) | ||
| 09.04. | H.C. Wainwright bestätigt Kaufempfehlung für Tscan-Aktie mit Kursziel 7 US-Dollar | 4 | Investing.com Deutsch | ||
| 09.04. | H.C. Wainwright reiterates Buy on Tscan stock, $7 target | 3 | Investing.com | ||
| 02.04. | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.03. | Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space | 1 | Insider Monkey | ||
| 04.03. | TScan Therapeutics GAAP EPS of -$0.18 beats by $0.06, revenue of $2.57M beats by $0.15M | 1 | Seeking Alpha | ||
| 04.03. | TScan Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 04.03. | TScan Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 04.03. | Earnings Breakdown: TScan Therapeutics Q4 | 1 | Benzinga.com | ||
| 04.03. | TScan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,85 | -0,13 % | BioNTech-Aktie: Ist das Unternehmen noch zu retten? | Die Geschichte von BioNTech ist eine der größten Erfolgsgeschichten der deutschen Wirtschaft. Aus einem Mainzer Forschungsunternehmen wurde innerhalb weniger Jahre ein globaler Pharmakonzern, dessen... ► Artikel lesen | |
| MEDIGENE | 0,021 | 0,00 % | Medigene AG: Widerruf der Zulassung zum regulierten Markt | Beschluss
Medigene AG, Planegg
Widerruf der Zulassung zum regulierten Markt
Auf Antrag der Gesellschaft wird die Zulassung der auf den Namen lautenden Stammaktien (ISIN: DE000A40ESG2) zum regulierten... ► Artikel lesen | |
| AMGEN | 315,00 | +0,17 % | Amgen - AMGN: Pharma-Aktie mit Cup & Handle! | Fliegt der Deckel bald weg? Kursziel Allzeithoch! Amgen (AMGN) erhöht Dividenden seit 2011! Dividendenrendite 2025: 2.91 Prozent! Amgen (AMGN) - US0311621009 Rückblick: Bei dem schwachen US-Gesamtmarkt... ► Artikel lesen | |
| BIOGEN | 190,00 | +0,08 % | Biogen ends Apellis research programs, cuts 'small number' of roles after $5.6B buyout | ||
| BIOFRONTERA | 2,330 | +0,43 % | PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse des ersten Quartals 2026 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DES ERSTEN QUARTALS 2026
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA BERICHTET ÜBER... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 554,60 | 0,00 % | Regeneron Pharmaceuticals, Inc.: Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG) | Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing FDA accepted NDA under Priority Review with a target... ► Artikel lesen | |
| EDITAS MEDICINE | 2,450 | -2,78 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| IMMATICS | 8,200 | -1,97 % | Immatics N.V. - S-8, Securities to be offered to employees in employee benefit plans | ||
| LAKEFRONT BIOTHERAPEUTICS | 25,140 | -2,18 % | Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer | ||
| AUTOLUS THERAPEUTICS | 1,400 | -2,10 % | Autolus Therapeutics plc: Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates | AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UKCompany achieves positive... ► Artikel lesen | |
| ONCOPEPTIDES | 0,140 | 0,00 % | Oncopeptides AB: First patient enrolled in Oncopeptides' real-world evidence study MARINA in Germany | STOCKHOLM - June 8, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company specializing in difficult-to-treat cancers, today announces that the first patient has been enrolled in... ► Artikel lesen | |
| TANGO THERAPEUTICS | 31,445 | -0,08 % | Tango Therapeutics, Inc.: Tango Therapeutics Appoints Robert Azelby to Board of Directors | BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| AVACTA | 0,840 | +3,07 % | Avacta agrees design of pivotal US cancer therapy trial | ||
| DERMATA THERAPEUTICS | 1,270 | -1,55 % | Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026 | - Dermata announced their Tome Skincare brand for direct-to-consumer ("DTC") skincare products -- Dermata plans to launch its first DTC product, the Tome Foundational Treatment, a once-weekly mask to... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 11,650 | +0,34 % | Lyell Immunopharma, Inc: Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion | Gastrointestinal prophylaxis reduced Grade = 2 diarrhea/colitis from 55% without prophylaxis to 10% with prophylaxisThe maximum tolerated dose has not yet been determinedNo difference is observed... ► Artikel lesen |
Das Unternehmen TSCAN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,45 % bei einem Aktienkurs von 0,955 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TSCAN THERAPEUTICS INC finden Sie auf Wallstreet Online.